A case of vulval basosquamous basal cell carcinoma with possible pelvic lymph node metastases

Background: Basal cell carcinoma (BCC) is the most common cutaneous neoplasm. It is most often a locally invasive tumour and rarely affects the vulva. Distant spread of BCC is rarer still and there are few cases reported of metastatic vulval primary tumours. Basosquamous carcinoma is regarded as a high-risk variant of BCC and its behaviour is unpredictable. Though more aggressive, it tends to grow locally rather than spread to lymph nodes as seen in squamous cell carcinoma (SCC). Case: We present a case of a basosquamous BCC arising in the vulva with involvement of the external and common iliac lymph nodes. Conclusion: Metastatic BCC has a poor prognosis and there are no definitive guidelines for its investigation or management. We recommend staging with imaging and potentially lymph node dissection in patients with large lesions involving underlying structures or aggressive histology.

Vulval cancer; Metastatic basal cell carcinoma; Gynaecology oncology; Staging radiology

[1] Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. New England Journal of Medicine. 2005; 353: 2262–2269.

[2] Dubas LE, Ingraffea A. Nonmelanoma skin cancer. Facial Plastic Surgery Clinics of North America. 2013; 21: 43–53.

[3] de Giorgi V, Salvini C, Massi D, Raspollini MR, Carli P. Vulvar basal cell carcinoma: retrospective study and review of literature. Gynecologic Oncology. 2005; 97: 192–194.

[4] Renati S, Henderson C, Aluko A, Burgin S. Basal cell carcinoma of the vulva: a case report and systematic review of the literature. International Journal of Dermatology. 2019; 58: 892–902.

[5] Weiss GJ, Korn RL. Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors. Cancer. 2012; 118: 5310–5319.

[6] Dalton AK, Wan KM, Gomes D, Wyatt JM, Oehler MK. Inguinal Metastasis from Basal Cell Carcinoma of the Vulva. Case Reports in Oncology. 2019; 12: 573–580.

[7] Mizushima J, Ohara K. Basal Cell Carcinoma of the Vulva with Lymph Node and Skin Metastasis. The Journal of Dermatology. 1995; 22: 36–42.

[8] Watson GA, Kelly D, Prior L, Stanley E, MacEneaney O, Walsh T, et al. An unusual case of basal cell carcinoma of the vulva with lung metastases. Gynecologic Oncology Reports. 2016; 18: 32–35.

[9] Benedet JL, Miller DM, Ehlen TG, Bertrand MA. Basal cell carcinoma of the vulva: clinical features and treatment results in 28 patients. Obstetrics and Gynecology. 1997; 90: 765–768.

[10] Fleury AC, Junkins-Hopkins JM, Diaz-Montes T. Vulvar basal cell carcinoma in a 20-year-old: Case report and review of the literature. Gynecologic Oncology Case Reports. 2011; 2: 26–27.

[11] Jimenez HT, Fenoglio CM, Richart RM. Vulvar basal cell carcinoma with metastasis: a case report. American Journal of Obstetrics and Gynecology. 1975; 121: 285–286.

[12] Sworn MJ, Hammond GT, Buchanan R. Metastatic basal cell carcinoma of the vulva. Case report. British Journal of Obstetrics and Gynaecology. 1979; 86: 332–334.

[13] Perrone T, Twiggs LB, Adcock LL, Dehner LP. Vulvar basal cell carcinoma: an infrequently metastasizing neoplasm. International Journal of Gynecological Pathology. 1987; 6: 152–165.

[14] Hoffman MS, Roberts WS, Ruffolo EH. Basal cell carcinoma of the vulva with inguinal lymph node metastases. Gynecologic Oncology. 1988; 29: 113–119.

[15] Winkelmann SE, Llorens AS. Metastatic basal cell carcinoma of the vulva. Gynecologic Oncology. 1990; 38: 138–140.

[16] Gleeson NC, Ruffolo EH, Hoffman MS, Cavanagh D. Basal cell carcinoma of the vulva with groin node metastasis. Gynecologic Oncology. 1994; 53: 366–368.

[17] Feakins RM, Lowe DG. Basal cell carcinoma of the vulva: a clinicopathologic study of 45 cases. International Journal of Gynecological Pathology. 1997; 16: 319–324.

[18] Sakai T, Goto M, Kai Y, Kato A, Shimizu F, Okamoto O, et al. Vulvar basal cell carcinoma with bone metastasis. Journal of Dermatology. 2011; 38: 97–100.

[19] Tellechea O, Reis JP, Domingues JC, Baptista AP. Monoclonal antibody Ber EP4 distinguishes basal-cell carcinoma from squamous-cell carcinoma of the skin. American Journal of Dermatopathology. 1993; 15: 452–455.

[20] Ramezani M, Mohamadzaheri E, Khazaei S, Najafi F, Vaisi-Raygani A, Rahbar M, et al. Comparison of EMA, CEA, CD10 and Bcl-2 Biomarkers by Immunohistochemistry in Squamous Cell Carcinoma and Basal Cell Carcinoma of the Skin. Asian Pacific Journal of Cancer Prevention. 2016; 17: 1379–1383.

[21] Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Applied Immunohistochemistry & Molecular Morphology. 2005; 13: 205–220.

[22] Calonje E. Mckee’s Pathology of the Skin: With Clinical Correlations. Edinburgh: Elsevier/Saunders, 2012.

[23] Namuduri R, Lim T, Yam P, Gatsinga R, Lim-Tan S, Chew S, et al. Vulvar basal cell carcinoma: clinical features and treatment outcomes from a tertiary care centre. Singapore Medical Journal. 2019; 60: 479–482.

[24] Ramdial PK, Madaree A, Reddy R, Chetty R. Bcl-2 protein expression in aggressive and non-aggressive basal cell carcinomas. Journal of Cutaneous Pathology. 2000; 27: 283–291.

[25] Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. International Journal of Gynecology & Obstetrics. 2009; 105: 103–104.

[26] Crivellaro C, Guglielmo P, De Ponti E, Elisei F, Guerra L, Magni S, et al. 18F-FDG PET/CT in preoperative staging of vulvar cancer patients: is it really effective? Medicine. 2017; 96: e7943.

[27] Cohn DE, Dehdashti F, Gibb RK, Mutch DG, Rader JS, Siegel BA, et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecologic Oncology. 2002; 85: 179–184.

[28] Kamran MW, O’Toole F, Meghen K, Wahab AN, Saadeh FA, Gleeson N. Whole-body [18F]fluoro-2-deoxyglucose positron emission tomography scan as combined PET-CT staging prior to planned radical vulvectomy and inguinofemoral lymphadenectomy for squamous vulvar cancer: a correlation with groin node metastasis. European Journal of Gynaecological Oncology. 2014; 35: 230–235.

[29] Signorelli M, Guerra L, Montanelli L, Crivellaro C, Buda A, Dell’Anna T, et al. Preoperative staging of cervical cancer: is 18-FDG-PET/CT really effective in patients with early stage disease?Gynecologic Oncology. 2011; 123: 236–240.

[30] Lin G, Chen C, Liu F, Yang L, Huang H, Huang Y, et al. Computed tomography, magnetic resonance imaging and FDG positron emission tomography in the management of vulvar malignancies. European Radiology. 2015; 25: 1267–1278.

[31] Silverman MK, Kopf AW, Bart RS, Grin CM, Levenstein MS. Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. Journal of Dermatologic Surgery and Oncology. 1992; 18: 471–476.

[32] Vu A, Laub D. Metastatic Basal cell carcinoma: a case report and review of the literature. Eplasty. 2011; 11: ic8.

[33] Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. New England Journal of Medicine. 2012; 366: 2171–2179.

[34] Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncology. 2015; 16: 716–728.

[35] Ozgediz D, Smith EB, Zheng J, Otero J, Tabatabai ZL, Corvera CU. Basal cell carcinoma does metastasize. Dermatology Online Journal. 2008; 14; 5.